A recent study has revealed promising results for the use of a drug similar to those found in “skinny jabs” in the treatment of Parkinson’s disease. According to research, GLP-1R agonists, such as the type 2 diabetes medication lixisenatide, have shown potential in slowing the progression of motor symptoms in individuals with Parkinson’s.
The study, which involved 156 participants with newly diagnosed Parkinson’s, divided the individuals into two groups. One group received lixisenatide while the other group received a placebo. After 12 months, those who were given lixisenatide displayed no progression of motor problems, while those on the placebo experienced worsening symptoms.
Despite these promising results, some participants receiving lixisenatide reported side effects such as nausea and vomiting. As a result, further research is required to determine the long-term effects, optimal dosage, and potential benefits for individuals in different stages of Parkinson’s disease.
Experts are optimistic about these findings and believe that they could lead to larger phase 3 clinical trials in the future. The study’s results suggest that GLP-1R agonists have the potential to be a valuable tool in the treatment of Parkinson’s disease.
For more updates on the latest research and developments in Parkinson’s disease treatment, stay tuned to ‘The Puck Drop’.
